17-Hydroxyprogesterone (17-OHP) is a steroid hormone produced primarily in the adrenal glands and, to a lesser extent, in the gonads (ovaries and testes). It serves as an important intermediate in the biosynthesis of cortisol and other steroid hormones, and is a crucial biomarker for diagnosing congenital adrenal hyperplasia (CAH), a group of genetic disorders affecting adrenal gland function. CAH can lead to an imbalance of hormones, particularly cortisol.
Reference ranges:
In females, normal levels of 17-OHP vary depending on age, menstrual cycle phase, and pregnancy status. Typically, the reference range for adult women is between 20 to 100 ng/dL in the follicular phase of the menstrual cycle, and 100-500 ng/dL during the luteal phase.
Abnormal levels:
Levels might be higher during pregnancy. When measuring 17-OHP, it's essential to consider these physiological variations to accurately interpret results.
High levels of 17-OHP in females are commonly associated with congenital adrenal hyperplasia (CAH), particularly the 21-hydroxylase deficiency type, which accounts for about 90% of cases. This enzyme deficiency leads to an accumulation of 17-OHP because it cannot be effectively converted into cortisol, resulting in excess androgen production.
Symptoms of elevated 17-OHP can include early or excessive hair growth (hirsutism), irregular menstrual cycles, infertility, and virilization (development of male characteristics). In severe cases, newborns may present with ambiguous genitalia. If 17-OHP levels are significantly high, further diagnostic tests like ACTH stimulation tests and genetic testing might be recommended to confirm CAH and determine its severity.
It's worth noting that 17-OHP testing, especially in newborn screening, can sometimes produce false-positive results. In such cases, additional tests like plasma renin activity, androstenedione, and testosterone may be performed for confirmation.
Treatment of high 17-OHP levels, particularly due to CAH, focuses on hormone replacement to balance cortisol and reduce excess androgen production. The standard treatment involves glucocorticoids like hydrocortisone, prednisone, or dexamethasone to suppress excess adrenal hormone production. Mineralocorticoids might also be required to balance salt levels, particularly in salt-wasting forms of CAH.
Regular monitoring of 17-OHP levels helps adjust medication dosages and ensures effective management of symptoms.
For women with milder forms of CAH or non-classical CAH, lower doses of corticosteroids or other medications, like oral contraceptives or anti-androgens, may be sufficient to manage symptoms.
It's important to note that 17-OHP has some biological activity of its own. It's a weak agonist of the progesterone receptor and an antagonist of the mineralocorticoid receptor, which could have implications for the clinical manifestations of elevated 17-OHP levels.
Conversely, low levels of 17-OHP are generally not a concern unless associated with other hormonal imbalances or clinical symptoms, in which case further investigation would be necessary. Regular follow-ups and a personalized treatment plan are crucial to managing hormone levels effectively and improving quality of life.
17-Hydroxyprogesterone (female)
Every lab result you’ve ever had, charted and explained.
Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.
Start with my report →
All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.